Globe on Big Pharma R&D Failure
3 Comments
Recent Posts
Rushing Lawful Access Backfires: Wyden Letter on Bill C-22 Highlights Political, Trade and Business Risks 
The Law Bytes Podcast, Episode 276: Information Commissioner Caroline Maynard on Canada’s Access to Information Failures and Why Access Delayed is Access Denied 
Why the Government’s Plan for a Social Media Ban in Bill C-34 Is Unconstitutional 
Outdated Data and Dubious Comparisons: Digging into the Government’s AI Strategy Adoption Claims 
Why Being Locked Out of Frontier AI is The Sovereignty Threat Canada Missed
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?